AstraZeneca's Brilinta Approved With Aspirin Warning
This article was originally published in The Pink Sheet Daily
Executive Summary
Anti-platelet ticagrelor carries a boxed warning that concomitant aspirin dose must be limited to 100 mg/day, a departure for U.S. prescribers accustomed to high-dose aspirin therapy.
You may also be interested in...
Research Fraud “Fruitful” Area For Government Probes; AstraZeneca Brilinta Trial In Crosshairs
HHS Office of Inspector General’s Mary Riordan advises drug makers to analyze their speaker programs and consulting arrangements for possible kickback activities.
AstraZeneca Deploys High-Sensitivity Troponin Test As Brilinta Biomarker
In PLATO post hoc analysis, researchers correlate results on new, more sensitive heart damage test from Roche with positive outcomes for Brilinta in preventing events in patients who are managed medically as well as invasively.
For Effient And Brilinta, A Formidable Competitor Grows More So
Plavix was a tough competitor before it went generic; now that cheap versions of the clot-buster are available, the market will prove even more challenging for the remaining branded antiplatelet drugs.